Sangamo showcases Fabry progress at WORLDSymposium™

Uncategorized

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease